Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes.

Kishimori T, Kato T, Wada A, Tani A, Yamaji R, Koike J, Iwasaki Y, Matsumoto T, Yagi T, Okada M

Scientific reports1 Jul 2025Cited by 1 (Europe PMC)

PMID40594279PMCIDPMC12217050DOI10.1038/s41598-025-06245-wPepBankPUB-40594279

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, semaglutide was associated with a lower 3-year risk of all-cause death than dulaglutide.
In plain wordsIn people with type 2 diabetes, semaglutide was linked to a lower risk of death over 3 years than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseAll-cause death over 3 years
Study
n = 342,210
Comparator
Dulaglutide
Analysis
Primary
Outcome group
Mortality · Cardiovascular
Studied dose
Dose not stated
Measurements
HR all-cause death
0.75 HR
semaglutide vs dulaglutide
Source sentences
Summary
Over 3 years, the risk for all-cause death in patients who received semaglutide relative to those who received dulaglutide was significantly lower (4.2% vs. 5.6%, p < 0.001; hazard ratio [HR] 0.75; 95% confidence interval [CI] 0.72-0.78)
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study used the TriNetX database of deidentified electronic medical records from January 1, 2018, to December 31, 2020.
Summary · context
After propensity score matching, 171,105 patients were included in each group.
Report a problemFND-4059427901
02HumanObservational studyEfficacy outcome
In adults with diabetes, dulaglutide use was linked to higher all-cause mortality than semaglutide over 3 years.
In plain wordsIn adults with diabetes, dulaglutide was linked to more deaths than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAll-cause death
Study
n = 342,210
Comparator
Semaglutide
Analysis
Primary
Outcome group
Mortality · Whole body
Studied dose
Dose not stated
Measurements
Mortality
5.6%
dulaglutide
Mortality
4.2%
semaglutide
Hazard ratio
0.75 ratio
semaglutide relative to dulaglutide
95% CI of hazard ratio
0.72 to 0.78 ratio
semaglutide relative to dulaglutide
Source sentences
Summary
Over 3 years, the risk for all-cause death in patients who received semaglutide relative to those who received dulaglutide was significantly lower (4.2% vs. 5.6%, p < 0.001; hazard ratio [HR] 0.75; 95% confidence interval [CI] 0.72-0.78).
2 context sentences(design, population, supporting numbers)
Summary · context
We compared all-cause death and cardiovascular events in patients using semaglutide or dulaglutide in patients with type 2 diabetes. This retrospective observational study used the TriNetX database of deidentified electronic medical records from January 1, 2018, to December 31, 2020.
Summary · context
After propensity score matching, 171,105 patients were included in each group.
Report a problemFND-4059427905
03HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, semaglutide was associated with a lower 3-year risk of acute myocardial infarction than dulaglutide.
In plain wordsIn people with type 2 diabetes, semaglutide was linked to a lower risk of heart attack than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseAcute myocardial infarction
Study
n = 342,210
Comparator
Dulaglutide
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
HR acute myocardial infarction
0.94 HR
semaglutide vs dulaglutide
Source sentences
Summary
acute myocardial infarction (5.2% vs. 5.6%; HR, 0.94; 95% CI, 0.91-0.97; p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study used the TriNetX database of deidentified electronic medical records from January 1, 2018, to December 31, 2020.
Summary · context
After propensity score matching, 171,105 patients were included in each group.
Report a problemFND-4059427902
04HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, semaglutide was associated with a lower 3-year risk of stroke than dulaglutide.
In plain wordsIn people with type 2 diabetes, semaglutide was linked to a lower risk of stroke than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseStroke
Study
n = 342,210
Comparator
Dulaglutide
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
HR stroke
0.9 HR
semaglutide vs dulaglutide
Source sentences
Summary
stroke (5.8% vs. 6.4%; HR, 0.90; 95% CI, 0.87-0.93; p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study used the TriNetX database of deidentified electronic medical records from January 1, 2018, to December 31, 2020.
Summary · context
After propensity score matching, 171,105 patients were included in each group.
Report a problemFND-4059427903
05HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, semaglutide was associated with a lower 3-year risk of acute heart failure than dulaglutide.
In plain wordsIn people with type 2 diabetes, semaglutide was linked to a lower risk of acute heart failure than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseAcute heart failure
Study
n = 342,210
Comparator
Dulaglutide
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
HR acute heart failure
0.88 HR
semaglutide vs dulaglutide
Source sentences
Summary
acute heart failure (5.3% vs. 6.1%; HR, 0.88; 95% CI, 0.85-0.91; p < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study used the TriNetX database of deidentified electronic medical records from January 1, 2018, to December 31, 2020.
Summary · context
After propensity score matching, 171,105 patients were included in each group.
Report a problemFND-4059427904
06HumanObservational studyEfficacy outcome
In adults with diabetes, dulaglutide use was linked to higher acute myocardial infarction risk than semaglutide.
In plain wordsIn adults with diabetes, dulaglutide was linked to more heart attacks than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAcute myocardial infarction
Study
n = 342,210
Comparator
Semaglutide
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Acute myocardial infarction
5.6%
dulaglutide
Acute myocardial infarction
5.2%
semaglutide
Hazard ratio
0.94 ratio
semaglutide relative to dulaglutide
95% CI of hazard ratio
0.91 to 0.97 ratio
semaglutide relative to dulaglutide
Source sentences
Summary
Similarly, patients who received semaglutide were less likely to have acute myocardial infarction (5.2% vs. 5.6%; HR, 0.94; 95% CI, 0.91-0.97; p < 0.001),
2 context sentences(design, population, supporting numbers)
Summary · context
We compared all-cause death and cardiovascular events in patients using semaglutide or dulaglutide in patients with type 2 diabetes. This retrospective observational study used the TriNetX database of deidentified electronic medical records from January 1, 2018, to December 31, 2020.
Summary · context
After propensity score matching, 171,105 patients were included in each group.
Report a problemFND-4059427906
07HumanObservational studyEfficacy outcome
In adults with diabetes, dulaglutide use was linked to higher stroke risk than semaglutide.
In plain wordsIn adults with diabetes, dulaglutide was linked to more strokes than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseStroke
Study
n = 342,210
Comparator
Semaglutide
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Stroke
6.4%
dulaglutide
Stroke
5.8%
semaglutide
Hazard ratio
0.9 ratio
semaglutide relative to dulaglutide
95% CI of hazard ratio
0.87 to 0.93 ratio
semaglutide relative to dulaglutide
Source sentences
Summary
stroke (5.8% vs. 6.4%; HR, 0.90; 95% CI, 0.87-0.93; p < 0.001),
2 context sentences(design, population, supporting numbers)
Summary · context
We compared all-cause death and cardiovascular events in patients using semaglutide or dulaglutide in patients with type 2 diabetes. This retrospective observational study used the TriNetX database of deidentified electronic medical records from January 1, 2018, to December 31, 2020.
Summary · context
After propensity score matching, 171,105 patients were included in each group.
Report a problemFND-4059427907
08HumanObservational studyEfficacy outcome
In adults with diabetes, dulaglutide use was linked to higher acute heart failure risk than semaglutide.
In plain wordsIn adults with diabetes, dulaglutide was linked to more acute heart failure than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAcute heart failure
Study
n = 342,210
Comparator
Semaglutide
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Acute heart failure
6.1%
dulaglutide
Acute heart failure
5.3%
semaglutide
Hazard ratio
0.88 ratio
semaglutide relative to dulaglutide
95% CI of hazard ratio
0.85 to 0.91 ratio
semaglutide relative to dulaglutide
Source sentences
Summary
and acute heart failure (5.3% vs. 6.1%; HR, 0.88; 95% CI, 0.85-0.91; p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
We compared all-cause death and cardiovascular events in patients using semaglutide or dulaglutide in patients with type 2 diabetes. This retrospective observational study used the TriNetX database of deidentified electronic medical records from January 1, 2018, to December 31, 2020.
Summary · context
After propensity score matching, 171,105 patients were included in each group.
Report a problemFND-4059427908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.